Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo has reaffirmed a Buy rating on Outlook Therapeutics (NASDAQ:OTLK) and increased the price target from $1.5 to $2.
December 29, 2023 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Outlook Therapeutics and raises the price target from $1.5 to $2.
The increase in price target by Ascendiant Capital suggests a positive outlook on the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100